Fox Foundation and Charles River renew Parkinson’s research collaboration

This is the second deal for Charles River this week. (Pixabay)

Charles River Laboratories and The Michael J. Fox Foundation for Parkinson’s Research have extended their collaboration, including grants to support work in protein phenotyping and the evaluation of small molecule inhibitors.

A new two-year project will focus on developing a baseline phenotype of alpha-synuclein knock-out and knock-in models, with the hope of creating a tool to assist drug discovery programs. Alpha-synuclein proteins form a major part of the clumps in the brain that are the hallmark of Parkinson’s disease, according to the foundation.

Charles River and MJFF have also renewed their ongoing efforts to test inhibitors of the LRRK2 enzyme, which has been genetically linked to development of the disease. The project hopes to determine optimal dosing while avoiding the lung toxicity reported in previous research.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Charles River and the foundation have collaborated on Parkinson’s disease research since 2011, and re-upped their relationship in late 2015.

RELATED: Charles River expands discovery services in the U.S. and Europe

The CRO, meanwhile, has been building out its capabilities in central nervous system research and drug discovery, through a series of acquisitions.

In August 2017, Charles River purchased the CNS-focused CRO Brains On-Line for about $21 million, which had offered preclinical services, pharmacokinetics analysis, microdialysis and in vivo efficacy testing of drugs in the brain, with operations in San Francisco, the Netherlands and Germany.

And earlier this year, Charles River acquired MPI Research for $800 million in cash.

The company said the early-stage drug development CRO will help expand its existing services in toxicology, including ophthalmology, juvenile toxicity, molecular biology and medical device testing, in addition to use of MPI’s 1 million-square-foot facility in Michigan.

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.